Holen Sie sich die Stockscreener-App
15.13
1.68%
0.25
Handel nachbörslich:
14.87
-0.26
-1.72%
Schlusskurs vom Vortag:
$14.88
Offen:
$14.81
24-Stunden-Volumen:
293.74K
Relative Volume:
0.45
Marktkapitalisierung:
$5.36B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-263.00M
KGV:
-19.56
EPS:
-0.7734
Netto-Cashflow:
$-167.84M
1W Leistung:
+3.21%
1M Leistung:
-0.39%
6M Leistung:
+23.51%
1J Leistung:
-27.50%
1-Tages-Spanne:
$14.75
$15.30
1-Wochen-Bereich:
$13.77
$15.30
52-Wochen-Spanne:
$10.45
$21.34
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
15.13 | 5.27B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
436.39 | 156.20B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
188.36 | 53.50B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
270.07 | 39.84B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
74.08 | 35.89B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
261.17 | 18.87B | 2.96B | 487.70M | 344.00M | 6.6758 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Stifel reiterates Buy rating on Bausch & Lomb stock, maintains $12 price target - Investing.com UK
Bausch + Lomb (NYSE:BLCO): Evaluating Valuation After Recent Earnings and Share Price Moves - Yahoo Finance
Analyzing drawdowns of Bausch + Lomb Corporation with statistical toolsMarket Movement Recap & Community Driven Trade Alerts - newser.com
Bausch + Lomb's (BLCO) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Global Myopia Treatment Devices Market Poised for Strong Growth at a CAGR of ~8% by 2032, Driven by Technological Innovations and Increasing Eye Care Demand | DelveInsight - GlobeNewswire Inc.
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Bausch + Lomb (NYSE:BLCO) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
What drives Bausch Lomb Corporation stock priceVolume Spike Alerts & Fast Growing Capital Growth - earlytimes.in
Bausch + Lomb Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
Can Bausch + Lomb Corporation (S2L) stock deliver strong annual returnsShare Buyback & Step-by-Step Trade Execution Guides - newser.com
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $16 - 富途牛牛
Assessing Bausch + Lomb (NYSE:BLCO) Valuation as Goldman Sachs Brings New Spotlight to Ophthalmology Growth Prospects - simplywall.st
Bausch + Lomb (NYSE:BLCO) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Is Bausch + Lomb Corporation (S2L) stock a momentum leaderMarket Risk Report & Consistent Income Trade Recommendations - newser.com
Applying Elliott Wave Theory to Bausch + Lomb CorporationQuarterly Market Review & Comprehensive Market Scan Reports - newser.com
Why Bausch + Lomb Corporation stock is upgraded to buy2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - newser.com
Goldman Sachs Initiates Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Announces Target Price $16 - 富途牛牛
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating - Investing.com
Is Zeal Aqua Limited a Smart Pick for Retirement PortfoliosEx-Dividend Date Alerts & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13 - BioSpace
Is Bausch + Lomb Corporation stock positioned for digital transformationMarket Growth Review & AI Driven Stock Reports - newser.com
Global Eye Health Leader Bausch + Lomb Announces Q3 Earnings Date and Strategic Investor Day Pipeline Review - Stock Titan
Will Bausch + Lomb Corporation stock benefit from Fed rate cutsBuy Signal & Real-Time Volume Surge Alerts - newser.com
Why Bausch + Lomb Corporation stock could be next leaderJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know - Yahoo Finance
1 Small-Cap Stock to Keep an Eye On and 2 That Underwhelm - The Globe and Mail
Applying chart zones and confluence areas to Bausch + Lomb CorporationIndex Update & Safe Swing Trade Setup Alerts - newser.com
Bausch + Lomb: There Are Better Opportunities Out There (Rating Downgrade) - Seeking Alpha
Trade Recap: Why is Bausch Lomb Corporation stock going upJuly 2025 Market Mood & Safe Capital Growth Tips - خودرو بانک
Goldman Sachs Group Inc. Grows Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corporation $BLCO Shares Sold by Dynamic Technology Lab Private Ltd - MarketBeat
Bausch + Lomb Corporation (NYSE:BLCO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Vident Advisory LLC Makes New Investment in Bausch + Lomb Corporation $BLCO - MarketBeat
Aug Shorts: Is Bausch Lomb Corporation exposed to currency risksEarnings Recap Report & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Clearline Capital LP Acquires 247,149 Shares of Bausch + Lomb Corporation $BLCO - MarketBeat
Cubist Systematic Strategies LLC Takes $2.12 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb (NYSE:BLCO): Valuation Perspective After New Clinical Data and ASANA Lens Launch - Yahoo Finance
Revolutionary Full Range Vision Lens: Bausch + Lomb's enVista Envy Succeeds in 501-Patient Trial - Stock Titan
Bausch + Lomb (BLCO) Study Shows XIIDRA Eye Drops Improve Comfort For Contact Lens Wearers - Sahm
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers - BioSpace
Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why - Yahoo Finance
Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues - 富途牛牛
Bausch + Lomb Corporation - Baystreet.ca
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):